Chrystyna Stecyk

Headquartered in New York City, Griffin Securities, Inc. is a research-driven investment banking firm providing corporate finance, merger & acquisitions, brokerage and investment opportunities for institutional, corporate and private clients. Orders can be entered on major U.S. exchanges and most international exchanges. Positions can be held in multiple currencies. Griffin's research focuses on delivering objective, value-added research and winning ideas in several industries including healthcare/biotechnology, technology and telecommunications. They are a member of the NASD and the SIPC. Griffin Securities was founded in 1997.

Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA.

Part of PTC Therapeutics, Inc., PTC Therapeutics GT, Inc. is a private company that innovates DNA therapeutics to provide long-term efficacy for patients with debilitating and fatal diseases. The company is based in Lynnfield, MA. The company was founded by Chrystyna Bedrij Stecyk.

Aletheia Biotherapeutics LLC operates as a clinical stage biotechnology company. It provides cancer-associated epithelial-to-mesenchyme transition with its AB-16B5 monoclonal antibody. The company is headquartered in New York, NY.

Orion Biotech Opportunities Corp. operates as a blank check company, which aims to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Zuie Chin Huang and Chrystyna Bedrij Stecyk on February 5, 2021 and is headquartered in New York, NY.

Myrtelle LLC is a gene therapy company that specializes in developing treatments for neurodegenerative diseases. Myrtelle is based in New York, NY. The company has a proprietary platform, intellectual property, and a portfolio of programs and technologies that support innovative gene therapy approaches. The company has an exclusive worldwide licensing agreement with Pfizer Inc. for its Canavan disease program.